KAPA · Kairos Pharma Ltd
United States · RS rating 55 · As of 2026-10-14
| Price | 0.74 USD |
|---|---|
| 1-day change | -10.3% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 2 / 98 / 18 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 28 / 31 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +25.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +59.8% |
| Market cap (USD) | $14.3M |